Compare Biocon Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CIPLA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CIPLA BIOCON /
CIPLA
 
P/E (TTM) x 23.0 23.5 97.8% View Chart
P/BV x 3.0 2.6 118.1% View Chart
Dividend Yield % 0.4 0.6 60.9%  

Financials

 BIOCON    CIPLA
EQUITY SHARE DATA
    BIOCON
Mar-18
CIPLA
Mar-19
BIOCON /
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,188678 175.2%   
Low Rs305484 63.0%   
Sales per share (Unadj.) Rs68.7198.2 34.7%  
Earnings per share (Unadj.) Rs7.618.5 40.8%  
Cash flow per share (Unadj.) Rs14.035.0 39.9%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %0.10.5 25.9%  
Book value per share (Unadj.) Rs86.3186.3 46.3%  
Shares outstanding (eoy) m600.00805.70 74.5%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.9 370.7%   
Avg P/E ratio x98.931.4 315.2%  
P/CF ratio (eoy) x53.416.6 321.8%  
Price / Book Value ratio x8.63.1 277.3%  
Dividend payout %13.216.2 81.8%   
Avg Mkt Cap Rs m447,900468,031 95.7%   
No. of employees `0006.122.6 27.2%   
Total wages/salary Rs m9,31128,565 32.6%   
Avg. sales/employee Rs Th6,705.87,053.1 95.1%   
Avg. wages/employee Rs Th1,514.21,261.5 120.0%   
Avg. net profit/employee Rs Th736.9659.1 111.8%   
INCOME DATA
Net Sales Rs m41,234159,710 25.8%  
Other income Rs m2,0624,766 43.3%   
Total revenues Rs m43,296164,475 26.3%   
Gross profit Rs m8,29130,973 26.8%  
Depreciation Rs m3,85113,263 29.0%   
Interest Rs m6151,684 36.5%   
Profit before tax Rs m5,88720,791 28.3%   
Minority Interest Rs m213-172 -124.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5695,695 27.5%   
Profit after tax Rs m4,53114,924 30.4%  
Gross profit margin %20.119.4 103.7%  
Effective tax rate %26.727.4 97.3%   
Net profit margin %11.09.3 117.6%  
BALANCE SHEET DATA
Current assets Rs m41,486124,266 33.4%   
Current liabilities Rs m21,41337,715 56.8%   
Net working cap to sales %48.754.2 89.8%  
Current ratio x1.93.3 58.8%  
Inventory Days Days6491 70.6%  
Debtors Days Days9495 99.3%  
Net fixed assets Rs m50,661105,190 48.2%   
Share capital Rs m3,0001,611 186.2%   
"Free" reserves Rs m48,808148,511 32.9%   
Net worth Rs m51,808150,123 34.5%   
Long term debt Rs m17,89838,301 46.7%   
Total assets Rs m99,897239,633 41.7%  
Interest coverage x10.613.3 79.2%   
Debt to equity ratio x0.30.3 135.4%  
Sales to assets ratio x0.40.7 61.9%   
Return on assets %5.26.9 74.3%  
Return on equity %8.79.9 88.0%  
Return on capital %9.611.8 81.4%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05857,410 21.0%   
Fx outflow Rs m7,34819,041 38.6%   
Net fx Rs m4,71038,368 12.3%   
CASH FLOW
From Operations Rs m6,62116,911 39.2%  
From Investments Rs m-6,840-16,687 41.0%  
From Financial Activity Rs m-2,397-3,487 68.7%  
Net Cashflow Rs m-2,612-3,451 75.7%  

Share Holding

Indian Promoters % 40.4 16.0 252.5%  
Foreign collaborators % 20.6 20.8 99.0%  
Indian inst/Mut Fund % 8.4 12.2 68.9%  
FIIs % 10.7 23.7 45.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 19.9 26.2 76.0%  
Shareholders   109,995 161,166 68.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   WOCKHARDT  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  VENUS REMEDIES  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits Fresh Record High; Vodafone Idea Among Top Gainers(12:30 pm)

After opening the day on a positive note, share markets in India continued their momentum to hit a fresh record high.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Nov 20, 2019 01:13 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS